NASDAQ: VRAXVirax Biolabs Group Ltd Stock
$3.19-0.26 (-7.54%)
Updated Aug 21, 2026
VRAX Price
$3.19
Fair Value Price
N/A
Market Cap
$1.85M
52 Week Low
$2.50
52 Week High
$21.75
P/E
-0.25x
P/B
0.24x
P/S
175.92x
PEG
N/A
Dividend Yield
N/A
Revenue
$12.42k
Earnings
-$5.02M
Gross Margin
61.9%
Operating Margin
-47,188.42%
Profit Margin
-40,439.1%
Debt to Equity
0.13
Operating Cash Flow
-$5M
Beta
0.94
Next Earnings
Oct 1, 2026
Ex-Dividend
N/A
Next Dividend
N/A
VRAX Overview
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VRAX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VRAX
Ranked#166 of 470
Ranked#166 of 470
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.24 | A | |
| $122.25 | A | |
| $7.20 | A |
Be the first to know about important VRAX news, forecast changes, insider trades & much more!
VRAX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VRAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VRAX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VRAX is good value based on its book value relative to its share price (0.24x), compared to the US Biotechnology industry average (5.61x)
P/B vs Industry Valuation
VRAX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VRAX due diligence checks available for Premium users.
Valuation
VRAX fair value
Fair Value of VRAX stock based on Discounted Cash Flow (DCF)
Price
$3.19
Fair Value
$13.75
Undervalued by
76.80%
VRAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VRAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.25x
Industry
18.13x
Market
18.35x
VRAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.24x
Industry
5.61x
VRAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VRAX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
VRAX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VRAX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.3M
Liabilities
$989.8k
Debt to equity
0.13
VRAX's short-term assets ($6.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRAX's short-term assets ($6.83M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRAX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VRAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
VRAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VRAX vs Biotech Stocks
Virax Biolabs Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.